NEW YORK, NY / ACCESSWIRE / March 3, 2017 / The Biotech's Post-Election rally gained some steam this week after President Trump labeled the U.S. Food and Drug Administration's drug approval process as "slow and burdensome" in his speech to Congress on Tuesday, February 28th. The iShares NASDAQ Biotechnology Index ETF and the SPDR S&P Biotech ETF have posted year-to-date gains of 12.97 percent and 19.28 percent, respectively. President Trump has previously vowed to slash current FDA regulations by "75% to 80%".

Register today for a free membership and gain access to daily research reports at: RDInvesting.com

In his first address to Congress, President Trump specifically talked about Megan Crowley, who was diagnosed with a rare genetic disorder Pompe disease, and is also the daughter of John F. Crowley, Chairman and CEO of Amicus Therapeutics. Megan's life was saved by a treatment created by a company that John started, Novazyme Pharmaceuticals.

"Our slow and burdensome approval process at the Food and Drug Administration keeps too many advances, like the one that saved Megan's life, from reaching those in need," President Trump in his speech to Congress on February 28th. "If we slash the restraints, not just at the FDA but across our government, then we will be blessed with far more miracles just like Megan."

Let's Take a Closer Look at Today's Trending Tickers

Sarepta Therapeutics' shares spiked 7.41 percent to close at $32.63 a share on Thursday. The stock traded between $31.65 and $34.33 on volume of 7.41 million shares traded. Analysts at Leerink Swann have recently upgraded the company's rating to "outperform" from "market perform". On February 28th, the company has reported adjusted net loss of $38.7 million or loss of $0.71 a share for the fourth quarter of 2016 as compared adjusted net loss of $58.3 million or $1.30 a share for the fourth quarter of 2015. The company had $329.3 million in cash, cash equivalents and restricted cash and investments as of December 31, 2016 compared to $204.0 million as of December 31, 2015. Consensus rating on the company is "outperform". Shares of Sarepta Therapeutics have gained approximately 18.96 percent.

"2016 was a transformative year, with the FDA accelerated approval of EXONDYS 51. In 2017, we are focused on our strategy to build shareholder value by executing a successful launch of EXONDYS 51 in the US, reaching more patients through global expansion, and rapidly advancing our pipeline through internal and external development efforts," said Edward Kaye, Sarepta's CEO, in the company's earnings release.

Access Today's Aurinia Pharmaceuticals Research Report Click Here

BioCryst Pharmaceuticals' shares jumped 8.16 percent to close at $7.42 a share on Thursday. The stock traded between $6.58 and $7.51 on volume 4.59 million shares traded. The company reported revenues were $9.0 million for the fourth quarter of 2016, compared to $4.6 million in the fourth quarter of 2015. Total revenue in the year 2016 decreased to $26.4 million from revenue of $48.3 million reported in the year 2015, primarily due to RAPIVAB out-licensing transaction to Seqirus and decrease in RAPIVAB product sales. Net loss was $4.5 million, or $0.06 per share, for the fourth quarter of 2016, compared to a net loss of $18.1 million, or $0.25 per share, in the comparable quarter a year ago.

On February 27th, the Company reported statistically significant and clinically meaningful reductions in attack frequency from an interim analysis of its ongoing APeX-1 clinical trial in patients with HAE.

Access Today's BioCryst Pharmaceuticals Research Report Click Here

Today's Features Includes:

Sarepta Therapeutics Inc. (NASDAQ: SRPT)

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com